RISalud
Institutional Health Repository of Andalucía
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10668/11613| Title: | Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. |
| Authors: | Moreso, Francesc Crespo, Marta Ruiz, Juan C Torres, Armando Gutierrez-Dalmau, Alex Osuna, Antonio Perelló, Manel Pascual, Julio Torres, Irina B Redondo-Pachón, Dolores Rodrigo, Emilio Lopez-Hoyos, Marcos Seron, Daniel |
| Keywords: | clinical research/practice;clinical trial;kidney (allograft) function/dysfunction;kidney transplantation/nephrology;pathology/histopathology;rejection: antibody-mediated (ABMR) |
| metadata.dc.subject.mesh: | Adult Allografts Chronic Disease Double-Blind Method Female Follow-Up Studies Glomerular Filtration Rate Graft Rejection Graft Survival HLA Antigens Humans Immunoglobulins, Intravenous Immunologic Factors Isoantibodies Kidney Failure, Chronic Kidney Function Tests Kidney Transplantation Male Middle Aged Postoperative Complications Prognosis Prospective Studies Risk Factors Rituximab Tissue Donors |
| Issue Date: | 24-Oct-2017 |
| Abstract: | There are no approved treatments for chronic antibody mediated rejection (ABMR). We conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate efficacy and safety of intravenous immunoglobulins (IVIG) combined with rituximab (RTX) (EudraCT 2010-023746-67). Patients with transplant glomerulopathy and anti-HLA donor-specific antibodies (DSA) were eligible. Patients with estimated glomerular filtration rate (eGFR) |
| URI: | http://hdl.handle.net/10668/11613 |
| metadata.dc.identifier.doi: | 10.1111/ajt.14520 |
| Appears in Collections: | Producción 2020 |
Files in This Item:
There are no files associated with this item.
This item is protected by original copyright |
Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.